Biocytogen’s Preclinical Services Division, currently focused in immuno-oncology, oncology, and autoimmunity, has established comprehensive in vivo and in vitro pharmacology capabilities and provided world class services to a broad spectrum of our customers.
At the core of our in vivo services are a large collection of genetically humanized mouse models of checkpoint inhibitors and cytokine/cytokine receptors, our highly immune-deficient B-NDG mice and their variants, including human immune reconstituted models using human PBMC and CD34+ engraftment, CDX (cell line-derived xenografts) and efficient engineering of desired cell line models for both in vivo and in vitro application. Based upon these models, our in vivo pharmacology platform provides in vivo efficacy, pharmacokinetics (PK), pharmacodynamics (PD) and biomarkers, and pathology and toxicology assessments. Complementary to our in vivo capabilities, our in vitro pharmacology platform performs immune cell profiling (e.g. tumor infiltrating lymphocytes (TIL) analysis), cytokine profiling, primary T, NK, and macrophage cell-based functional assays such as T cell activation, mixed-lymphocyte reaction (MLR), T cell cytotoxicity, antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), target binding, receptor occupancy (RO), cell proliferation and cell death, and cell reporter assays.
We have successfully supported our pharmaceutical and biotech customers in evaluating therapeutics of multiple forms, including biologics (monoclonal antibodies, bispecific antibodies, and recombinant proteins), peptides, small molecules, cell therapy of CAR-T, and oncolytic viruses. In 2018, our Preclinical Services Division has completed over 500 drug evaluation projects for more than 200 partners worldwide. We also successfully assisted our customers in IND applications. Supported by Biocytogen’s large-scale generation of new animal models and advanced gene editing technology, our Preclinical Services Division will continue to deliver high-quality, timely and cost-effective services, provide comprehensive and accurate data, and facilitate the drug discovery and development processes for our customers.
We generated several mouse models to evaluate the preclinical in vivo efficacy of immunotherapy drugs, including humanized immune-checkpoint mice, human immune system engrafted mouse models as well as CDX.
Biocytogen provides robust animal models, such as those of experimental autoimmune encephalomyelitis (EAE), psoriasis, and asthma.
Leveraging our scientists’ rich experience, we provide high quality studies in in vivo efficacy, PK/PD, toxicity, and in vitro assays with a broad range of end points or readouts.